PERRY M. WESTBERRY, PA-C

550 Peachtree Street, NE Suite 1700
Atlanta, GA 30308

Phone (404) 881-9727
Fax (404) 523-9184

EDUCATION

1999	Luther Rice Seminary, Biblical Studies Program
1997 – 1998	New Orleans Baptist Theological Seminary, New Orleans, LA Pastoral Ministries Program
1983	PA-C - Informally trained, passed NCCPA board exam
1976 – 1978	Clayton State College, Morrow, Georgia, Degree: AA - Nursing
1968 – 1972	Georgia Institute of Technology, Atlanta, GA, studied chemistry, biology, & health systems engineering

MEDICAL EXPERIENCE

2001 – 2009	Investigator, Georgia Clinical Research (formerly Radiant Research Atlanta-West), Austell & Atlanta, GA (formerly Protocare Trials - Southeast Research Associates)
1972 – Present	Physician Assistant/ Sub-Investigator, The Kaufmann Clinic, Atlanta, GA
2009 – Present	Physician Assistant, Brightpoint Urgent Care, Stockbridge, Georgia (Part time)

CERTIFICATION AND LICENSURE

1983 – Present	National Commission on Certification of Physician Assistants Recertification by examination 1990 Recertification by Alternate Pathway pilot study 1996 Recertification by Alternate Pathway 2002, 2008 Re-registration by CME (100 Hours) every two years

LICENSURE:

Georgia Board of Nursing - Registered Professional Nurse
License Number: 054938 (1978 – 2003)

State of Georgia –Physician Assistant
License Number: 001093

PROFESSIONAL AND ACADEMIC APPOINTMENTS

2010 – Present	Adjunct Clinical Assistant Professor, guest lecturer, Mercer University Physician Assistant Program
2010 – Present	Clinical Preceptor, Albany State University, Nurse Practitioner Program
2010 – Present	Clinical Preceptor, University of Alabama, Birmingham, Nurse Practitioner Program
2009 – Present	Clinical Associate, Nova Southeastern University Physician Assistant Program
2009 – Present	Physician Assistant Advisory and Development Committee, Mercer University Physician Assistant Program
2008 – 2010	Clinical Instructor, Mercer University Physician Assistant Program
2007 – Present	Clinical Instructor, East Virginia Medical School Physician Assistant Program

2007 – Present	Clinical Preceptor, Kennesaw State University Nurse Practioner Program
2003 – Present	Clinical Faculty, Byrdine F. Lewis School of Nursing, College of Health and Human Sciences, Georgia State University, Atlanta, GA
2001 – 2011	Clinical Faculty, South University Physician Assistant Program Savannah, GA
1999 – Present	Adjunct Clinical Faculty, Medical College of Georgia Physician Assistant Program, Augusta, GA
1994 – 2011	Clinical Preceptor, Medical College of Georgia Physician Assistant Program Augusta, GA

Also serve occasionally as Clinical Preceptor for Physician Assistant programs at Duke University, Butler University PA Program, Nova Southeastern PA Program; Medical University of South Carolina PA program as well as Preceptor for Nurse Practitioner programs at Albany State, University of Alabama, and Walden University.

INSTITUTIONAL AFFILIATIONS

1984 – Present	Emory Midtown (Crawford Long) Hospital, Atlanta, GA

PROFESSIONAL ORGANIZATIONS

2000	Listed Marquis' Who 's Who in American, Medicine and Healthcare
1999 – 2000	Christian Medical and Dental Society
1994 – 2000	Crawford Long Hospital – Ethics Committee
1990 – 2002	Fellowship of Christian Physician Assistants, Board of Directors 1998 – 2001 Editor FCPA Newsletter 1998 – 2001
1985 – 1987	Utilization Review Committee – Crawford Long Hospital
1984 – Present	American Academy of Physician Assistants
1984 – 2001	Georgia Association of Physician Assistants Director-at-Large (2 terms) Chairman Membership Committee 3 years Chairman ad hoc task force on impaired practitioners, founding chairman of the standing committee 2 years
1984	Charter Member International Society for Hypertension in Blacks

CLINICAL RESEARCH EXPERIENCE

1. A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen. (207340)
   Sub-Investigator: Perry M. Westberry, PA-C

2. A randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy & Safety of XXX in Subjects with Generalized Erectile Dysfunction (207297)
   Sub-Investigator: Perry M. Westberry, PA-C

3. Assessment of the effect of XXX and naproxen sodium combination tablet, XXX tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults (207296)
   Sub-Investigator: Perry M. Westberry, PA-C

4. Maintain Effect of XXX In Obesity Treatment: Effect of XXX on long-term weight maintenance following weight loss induced by a 12 week low calorie diet in obese subjects; A 52

week randomized, double-blind, placebo controlled, parallel group, multi-centre trial with a 12 week follow-up period (207295)
Sub-Investigator: Perry M. Westberry, PA-C

5. A dose-ranging study evaluating the efficacy, safety and tolerability of XXXX in the prophylactic treatment of migraine headache (207294)
Sub-Investigator: Perry M. Westberry, PA-C

6. An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo with Background Metformin Treatment in Patients with Type 2 Diabetes Mellitus (207293)
Sub-Investigator: Perry M. Westberry, PA-C

7. A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist XXX(50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder (207292)
Sub-Investigator: Perry M. Westberry, PA-C

8. A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist XXX in Subjects with Symptoms of Overactive Bladder (207291)
Sub-Investigator: Perry M. Westberry, PA-C

9. An 8 week prospective, Multi-Center, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate and Efficacy & Safety of XXX versus XXX in African American Patients with Stage 2 Hypertension. (207290)
Sub-Investigator: Perry M. Westberry, PA-C

10. A 16 week multi-center, randomized, double-blind study to evaluate efficacy and safety of XXX combination therapy compared to patients initiated with XXX or hydrochlorothiazide monotherapy in very elderly patients with essential hypertension (207288)
Sub-Investigator: Perry M. Westberry, PA-C

11. Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of XXX and Celecoxib 200 mg QD in Patients with Osteoarthritis of the Knee (207284)
Sub-Investigator: Perry M. Westberry, PA-C

12. A 16-Week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-controlled, Parallel-Group Pharmacological study, to Assess the Effect of Naproxcinod (375 mg and 750 mg, bid) compared to equimolar doses of Naproxen (250mg and 500 mg, bid) and to Ibuprofen (600mg, tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients with Controlled Essential Hypertension (207278)
Sub-Investigator: Perry M. Westberry, PA-C

13. A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Black Subjects with Essential Hypertension (207271)
Sub-Investigator: Perry M. Westberry, PA-C

14. The Efficacy and Safety of XXX in the Treatment of Osteoarthritis of the Knee: Pivotal Study I (207266)
Sub-Investigator: Perry M. Westberry, PA-C

15. A rapid onset and short duration insulin secretagogue, mitiglinide, in combination with metformin versus metformin alone in patients with Type 2 diabetes mellitus: A Randomized, Double-Blind, Placebo-Controlled trial for 6 months. (207265)
    Sub-Investigator: Perry M. Westberry, PA-C

16. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Trexima™ (Sumatriptan + Naproxen Sodium) versus XXX containing medications XXX for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Study 1 of 2) (207263)
    Sub-Investigator: Perry M. Westberry, PA-C

17. A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of XXX in Subjects with Essential Hypertension. (207261)
    Sub-Investigator: Perry M. Westberry, PA-C

18. A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of XXX: 26-Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks)- and Naproxen (26 Weeks)- Controlled, Multicenter Study of XXX (375 mg bid and 750 mg bid) with a 26-Week Naproxen-Controlled Safety Follow-up in Subjects with Osteoarthritis of the Knee, and a 1-Week Post-treatment Safety Follow-up. (207260)
    Sub-Investigator: Perry M. Westberry, PA-C

19. A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of XXX Sustained Release (SR)/XXX Sustained Release (SR) and Placebo in Obese Subjects (207256)
    Sub-Investigator: Perry M. Westberry, PA-C

20. A Phase II, Multicenter, Randomized, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular XXX in Subjects with Uncomplicated Acute Influenza (207255)
    Sub-Investigator: Perry M. Westberry, PA-C

21. A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail (207252)
    Sub-Investigator: Perry Westberry, PA-C

22. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA™ (sumitriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (207094)
    Sub-Investigator: Perry M. Westberry, PA-C

23. Multicenter, randomized, double-blind titration study to evaluate and compare the efficacy and safety of XXX added on to XXX40 mg versus up titration to XXX 80 mg in Hypercholesterolemic patients at high risk for coronary heart disease not adequately controlled on XXX 40 mg. (207089)
    Sub-Investigator: Perry Westberry, PA-C

24. A Phase II, Randomized, Double-Blind, Placebo-controlled, Proof of Concept, Efficacy and Safety Study of XXX and Naproxen in Treating the Signs and Symptoms of Osteoarthritis of the Knee (206910)

Sub-Investigator: Perry Westberry, PA-C

25. A Parallel, Randomized, Open-Label, Multi-Center, 52-Week Follow-up Study of XXXX (375 mg bid and 750 mg bid) in Subjects with Osteoarthritis of the Knee (Follow-up of the 13-Week, Double-Blind, Parallel, Randomized Placebo- and Naproxen-Controlled XXXX Efficacy and Safey Study. (206886)
    Sub-Investigator: Perry Westberry, PA-C

26. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of XXX in Subjects With Mild to Moderate Uncomplicated Essential Hypertension (206865)
    Sub-Investigator: Perry Westberry, PA-C

27. Patient outcome with education, drug therapy, and support (POETS): A multicenter, open label randomized study to evaluate depressed subjects treated with Venlafaxine™ extended release vs Venlafaxine™ extended plus the dialog time to talk program in a primary care setting. (206762)
    Sub-Investigator: Perry Westberry, PA-C

28. A Phase III, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of fourteen day treatment with lansoprazole 15 mg once a day in frequent heartburn (206687)
    Sub-Investigator: Perry Westberry, PA-C

29. A randomized, double-blind, active-controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of XXX versus acyclovir cream for treatment of recurrent herpes simplex labialis (206690)
    Sub-Investigator: Perry Westberry, PA-C

30. A double-blind, randomized, parallel-group, dose ranging, Multi-center study to evaluate the efficacy and safety of XXX once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment in patients with mild to moderate hypertension. (#206248)
    Sub-Investigator: Perry Westberry, PA-C

31. A Multi-center, randomized, double-blind, prospective study comparing the safety and efficacy of XXX and XXX calcium combination therapy to XXX and XXX calcium monotherapy in subjects with mixed dyslipidemia. (#205743)
    Sub-Investigator: Perry Westberry, PA-C

32. A Phase 3 study of the Analgesic Efficacy and Safety of HCT 3012: a Parallel, Randomized, Double-Blind, 13-week Placebo- and Naproxen-Controlled, Multicenter Study of XXX(375 mg bid and 750 mg bid) in Patients with Osteoarthritis of the Knee (#205708) Sub-Investigator: Perry Westberry, PA-C.

33. An eight-week randomized, double-blind, parallel group, Multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of XXX administered alone and in combination with XXX in patients with hypertension. (#205280)
    Sub-Investigator: Perry Westberry, PA-C

34. A randomized, double-blind, Multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima ™ (XXX) administered during the mild pain phase for the acute treatment of multiple migraine attacks. (#205603)
    Sub-Investigator: Perry Westberry, PA-C

35. Randomized, double-blind trial of XXX 350 mg and 250 mg tablets compared to placebo in patients with Acute, Painful Musculoskeletal Spasm of the Lower Back (#205717)
Sub-Investigator: Perry Westberry, PA-C

33. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of XXX in Subjects With Mild to Moderate Uncomplicated Essential Hypertension (206865)
Sub-Investigator: Perry Westberry, PA-C

34. An open-label, randomized study evaluating the long-term effects of XXX versus XXX as monotherapy or in combination with XXX or XXX for the treatment of patients with hypertension (#206108)
Sub-Investigator: Perry Westberry, PA-C

35. A placebo-controlled, randomized, double-blind, Fixed-Dose, at-home study to evaluate the efficacy and safety of intranasally administered XXX in Subjects with Erectile Dysfunction and Diabetes Mellitus (#205337)
Sub-Investigator: Perry Westberry, PA-C

36. A placebo-controlled, randomized, double-blind, fixed-dose, at-home study to evaluate the Efficacy and Safety of Intranasally Administered XXX in Subjects with Erectile Dysfunction (#203781)
Sub-Investigator: Perry Westberry, PA-C

37. A randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of XXX in subjects with muscle strain. (#205117)
Sub-Investigator: Perry Westberry, PA-C.

38. A double-blind, randomized, prospective trial to evaluate the efficacy and safety of XXX versus placebo in subjects with Major Depressive Disorder with suboptimal response to standard antidepressant therapy. (#203503)
Sub-Investigator: Perry Westberry, PA-C

39. An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of XXXX in patients with primary osteoarthritis of the hand. (#205017)
Sub-Investigator: Perry Westberry, PA-C

40. A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of XXX in patients with generalized anxiety disorder. (#205059)
Sub-Investigator: Perry Westberry, PA-C

41. A Double-blind, Randomized, Placebo- and Active-controlled, Forced Titration Study Evaluating the effects of XXX on Blood Pressure and Heart Rate in African American Patients with Hypertension. (#204693)
Sub-Investigator: Perry Westberry, PA-C

42. A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of XXX in patients with primary hip osteoarthritis using XXX as a positive control. (#203505)
Sub-Investigator: Perry Westberry, PA-C.

43. The Efficacy and Safety of XXXX Combination Therapy as First Line Treatment for Patients with Moderate Hypertension (#204428)
    Sub-Investigator: Perry Westberry, PA-C

44. An uncontrolled long-term safety trial of XXXX in patients with O.A. of the Knee (#204830)
    Sub-Investigator: Perry Westberry, PA-C

45. A Randomized, Double-blind, Parallel Group, Placebo-controlled, Single-attack Evaluation of the Efficacy and Tolerability of XXXX Tablets vs Placebo When Administered During the Mild Pain Phase of a Migraine. (#204736)
    Sub-Investigator: Perry Westberry, PA-C

46. The Efficacy and Safety of XXXX Combination Therapy as First Line Treatment for Severe Hypertension (#204322)
    Sub-Investigator: Perry Westberry, PA-C

47. A Randomized, Double-Blind, Placebo-Controlled Study Evaluating XXXX Extended Release in the Treatment of Osteoarthritis of the Hip or Knee. (#203319)
    Sub-Investigator: Perry Westberry, PA-C

48. A prospective, multinational, multicenter, double-blind, randomized, active-controlled trial to compare the effects of XXXX to XXXX and XXXX combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension – ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension) (#202832)
    Sub-Investigator: Perry Westberry, PA-C

49. A 12 week randomized double-blind multicenter vehicle controlled parallel group study to assess the efficacy and safety of XXXX for the relief of signs and symptoms in patients with O.A. of the knee. (#204458)
    Sub-Investigator: Perry Westberry, PA-C

50. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of XXXX in Patients 18 - 70 Years of Age with Symptoms of Overactive Bladder (#203870)
    Sub-Investigator: Perry Westberry, PA-C

51. A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of XXXX in Patients with Osteoarthritis or Rheumatoid Arthritis (#201465)
    Sub-Investigator: Perry Westberry, PA-C

52. A phase III open label study randomized allopurinol-controlled study to assess the long term safety of XXXX in subjects with gout (#202413)
    Sub-Investigator: Perry Westberry, PA-C

53. The Efficacy and Safety of XXXX Combination Therapy as First Line Treatment for Severe Hypertension (#204322)
    Sub-Investigator: Perry Westberry, PA-C

54. The Safety, Tolerability, and Immunogenicity of XXXX Smallpox Vaccine in Adults Without Previous Smallpox Vaccination. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison Between XXXX 2000 and XXXX Smallpox Vaccine. (#201873)
    Sub-Investigator: Perry Westberry, PA-C

55. A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of XXXX in Patients with Non-Cancer- Related Pain and Opioid-Induced Constipation (OIC)

56. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

57. A Multi-Center Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of XXXX and XXXX in Subjects with Gout and Cardiovascular Comorbidities.

58. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term XXXX Treatment for the Prevention of Gout Flares.

59. A Randomized, Double-Blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXX/XXX Controlled-release Tablets to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to XXX Controlled-release Tablets (XXX)) in Opioid-experienced Subjects with Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy, Purdue Pharma LP, Phase 3, December 2012-present

60. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome, Furiex Pharmaceuticals, November 2012-present

61. 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of XXX and XXX in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs with a 6-month Safety Extension Period, Sanofi, December 2012- present

62. The Safety, Tolerability, and Immunogenicity of XXXX Smallpox Vaccine in Adults with Previous Smallpox Vaccination. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison Between XXXX and XXXX Smallpox Vaccines. (#203095)
    Sub-Investigator: Perry Westberry, PA-C

63. A 26 –week, Double-Blind, Randomized, Multi-Center, Phase IIIB, Parallel Group Study to Compare the Efficacy and Safety of XXXX (40mg) with XXXX (80mg) in Subjects with Hypercholesterolemia and Coronary Heart Disease or CHD Risk Equivalents (#202322)
    Sub-Investigator: Perry Westberry, PA-C

64. A Randomized, Double-Blind, Placebo-Controlled Study Evaluating XXXX Extended Release (3900 mg/day) in the Treatment of Osteoarthritis of the Hip or Knee. (#203399)
    Sub-Investigator: Perry Westberry, PA-C

65. A Randomized, Controlled Study of XXXX (250 mcg and 500 mcg) versus Placebo in XXXX Randomized, Controlled Study of XXXX (250 mcg and 500 mcg) versus Placebo in Patients with Asthma. (#203122)
    Sub-Investigator: Perry Westberry, PA-C

66. A Phase IIIB, Multi-Center, Double-Blind Clinical Study to Evaluate the Safety and Tolerability of XXXX, Ultra-Lo Following a Run-In of XXXX Extended Regimen Oral Contraceptive Therapy. (#201784)
    Sub-Investigator: Perry Westberry, PA-C

67. Symptom Specific Effectiveness of XXXX 4 mg in Patients with Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open –Label, Single Arm, Non-Randomized Trial in Adult Patients with OAB. (#203272)
    Sub-Investigator: Perry Westberry, PA-C

68. A Prospective, Multi-national, Multi-Center, Double-Blind, Randomized, Active-Controlled Trial to Compare the Effects of XXXX to XXXX and XXXX Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension. (#202832)
    Sub-Investigator: Perry Westberry, PA-C

69. An Open-Label, Long-Term, Phase 3 Trial of the Safety and Efficacy of XXXX in Male Subjects with Erectile Dysfunction. (#203292)
    Sub-Investigator: Perry Westberry, PA-C

70. A Randomized, Placebo-Controlled, Double-Blind Parallel Design Phase 3 Bridging Trial of the Efficacy and Safety of XXXX 300mcg in Male Subjects with Erectile Dysfunction. Principal Sub-Investigator: Perry Westberry, PA-C

71. A Multi-Center, Randomized, Double-Blind, Double-Dummy Comparative Trial of XXXX Versus XXXX Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults. (#201623
    Sub-Investigator: Perry Westberry, PA-C

72. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties (#4889x1)
    Sub-Investigator: Perry Westberry, PA-C

73. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties (#4889)
    Sub-Investigator: Perry Westberry, PA-C

74. A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of XXXX vs. XXXX in the Treatment of Acute Gouty Arthritis
    Sub-Investigator: Perry Westberry, PA-C. (#4778)

75. A Phase III Randomized, Multicenter Study Comparing the Safety and Efficacy of XXXX versus XXXX in Subjects with Gout (#4630)
    Sub-Investigator: Perry Westberry, PA-C

76. A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of XXXX in Patients with Osteoarthritis or Rheumatoid Arthritis
    Sub-Investigator: Perry Westberry, PA-C. (#4536)

77. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral XXXX 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder (IHS 1.7)
    Sub-Investigator: Perry Westberry, PA-C. (#4488)

78. An Open-Label, Parallel Design, Twelve Month Phase 3 Trial of the Safety and Efficacy of XXXX in Male Patients with Erectile Dysfunction (#4453)
    Sub-Investigator: Perry Westberry, PA-C

79. A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 3 Trial Of The Efficacy And Safety Of XXXX In Male Patients With Erectile Dysfunction (#4357)
    Sub-Investigator: Perry Westberry, PA-C

80. A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of XXXX 50mg Tablets versus Placebo in the Treatment of Self-Described and/or Physician-Diagnosed Sinus Headaches that Meet International Headache Society (IHS) Criteria for Migraine Headache (#4147)
    Sub-Investigator: Perry Westberry, PA-C Completed: April 2002

81. Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study (#3783)
    Sub-Investigator: Perry Westberry, PA-C Completed: December 2001

82. A Phase III, Double-Blind, Randomized, Placebo Controlled Study of XXXX in Severely Obese Subjects (#3696a1)
    Sub-Investigator: Perry Westberry, PA-C

83. A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study of Ascending Doses of XXXX, XXXX and XXXX in Patients with Essential Hypertension (#3668)
    Sub-Investigator: Perry Westberry, PA-C Completed: July 2002

84. Double-Blind, Placebo and Active Controlled Study of Sustained Release XXXX In Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence (#3641)
    Sub-Investigator: Perry Westberry, PA-C Completed: December 2001

85. The Efficacy and Safety of 5 Days Oral XXXX Versus 10 Days Oral XXXX in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) (#3628)
    Sub-Investigator: Perry Westberry, PA-C Completed: June 2002

86. An Open-Label Continuation Trial of XXXX (Topical Gel Formulation of XXXX and XXXX) in Male ED Patients Who Previously Participated in XXXX (#3601x1)
    Sub-Investigator: Perry Westberry, PA-C Completed: March 2002

87. A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of XXXX (Topical Gel Formulation of XXXX and XXXX) for the Treatment of Male Erectile Dysfunction in an At-Home Setting (#3601)
    Sub-Investigator: Perry Westberry, PA-C. Completed: December 2001

88. A Randomized, Double-Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of XXXX in Adult Subjects with Insomnia (#3572a1)
    Sub-Investigator: Perry Westberry, PA-C.

89. A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of XXXX in Patients with Non-Cancer- Related Pain and Opioid-Induced Constipation (OIC)
    Sub-Investigator: Perry Westberry, PA-C

90. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)
    Sub- Investigator: Perry Westberry, PA-C

91. A Multi-Center Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of XXXX and XXXX in Subjects with Gout and Cardiovascular Comorbidities.
    Sub- Investigator: Perry Westberry, PA-C

92. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term XXXX Treatment for the Prevention of Gout Flares.
    Sub- Investigator: Perry Westberry, PA-C